Ensign Peak Advisors Inc Grows Stock Position in Insmed Incorporated (NASDAQ:INSM)

Ensign Peak Advisors Inc boosted its stake in shares of Insmed Incorporated (NASDAQ:INSM) by 5.1% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 359,029 shares of the biopharmaceutical company’s stock after acquiring an additional 17,455 shares during the quarter. Ensign Peak Advisors Inc owned 0.24% of Insmed worth $24,055,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of the stock. EntryPoint Capital LLC purchased a new stake in shares of Insmed during the first quarter valued at approximately $33,000. Fidelis Capital Partners LLC purchased a new position in shares of Insmed in the first quarter valued at about $34,000. First Horizon Advisors Inc. increased its position in shares of Insmed by 83.4% in the second quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 287 shares during the period. Headlands Technologies LLC purchased a new stake in shares of Insmed during the first quarter worth about $59,000. Finally, CWM LLC grew its stake in shares of Insmed by 11.0% in the second quarter. CWM LLC now owns 1,570 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 155 shares during the last quarter.

Insider Activity at Insmed

In other Insmed news, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the business’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $71.50, for a total value of $2,686,612.50. Following the completion of the transaction, the insider now owns 100,100 shares of the company’s stock, valued at approximately $7,157,150. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $71.50, for a total value of $2,686,612.50. Following the sale, the insider now owns 100,100 shares in the company, valued at $7,157,150. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Michael Alexander Smith sold 27,871 shares of the business’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $74.35, for a total transaction of $2,072,208.85. Following the sale, the insider now owns 67,856 shares of the company’s stock, valued at $5,045,093.60. The disclosure for this sale can be found here. Insiders have sold 78,882 shares of company stock valued at $5,765,446 over the last ninety days. Insiders own 4.60% of the company’s stock.

Wall Street Analyst Weigh In

INSM has been the subject of several research analyst reports. Stifel Nicolaus increased their price objective on Insmed from $74.00 to $88.00 and gave the stock a “buy” rating in a report on Friday, August 9th. UBS Group upped their price objective on shares of Insmed from $78.00 to $84.00 and gave the stock a “buy” rating in a report on Friday, August 9th. HC Wainwright reiterated a “buy” rating and set a $90.00 price target on shares of Insmed in a research report on Thursday, August 29th. Bank of America restated a “buy” rating and issued a $83.00 price objective on shares of Insmed in a report on Friday, July 5th. Finally, The Goldman Sachs Group increased their target price on Insmed from $74.00 to $102.00 and gave the stock a “buy” rating in a research report on Wednesday, July 10th. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. According to data from MarketBeat, Insmed presently has a consensus rating of “Moderate Buy” and a consensus price target of $81.40.

Insmed Stock Down 1.0 %

Shares of Insmed stock opened at $74.21 on Monday. The company has a 50-day simple moving average of $74.68 and a two-hundred day simple moving average of $52.21. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $80.53. The company has a debt-to-equity ratio of 25.05, a quick ratio of 2.53 and a current ratio of 2.71. The stock has a market capitalization of $11.03 billion, a PE ratio of -14.19 and a beta of 1.11.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($1.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.22) by ($0.72). The company had revenue of $90.34 million during the quarter, compared to analyst estimates of $87.95 million. The company’s quarterly revenue was up 17.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.78) earnings per share. On average, analysts anticipate that Insmed Incorporated will post -5.42 EPS for the current fiscal year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.